- Details
- By Native News Online Staff
WASHINGTON — The Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC) on Friday evening lifted its pause of the Johnson & Johnson/Janssen COVID-19 vaccine.
Soon thereafter, the Indian Health Service (IHS) followed suit on Friday at 10 p.m. - EDT and lifted the pause among the Indian health system.
“Indian Health Service facilities will resume administration of the Johnson & Johnson/Janssen COVID-19 vaccine. IHS originally paused administration of the Johnson & Johnson/Janssen COVID-19 vaccine to allow the FDA and CDC to review data involving six reported U.S. cases of a rare and severe type of blood clot in individuals receiving the vaccine,” IHS said in a statement.
IHS has vaccine safety monitoring systems in place. To date, there have been no cases reported through IHS of the rare and severe type of blood clot seen in some individuals who have received the Johnson & Johnson/Janssen COVID-19 vaccine.
The FDA and CDC said in a statement the two agencies have confidence that this vaccine is safe and effective in preventing Covid-19.
The FDA has determined that the available data show that the vaccine’s known and potential benefits outweigh its known and potential risks in individuals 18 years of age and older.
IHS originally paused administration of the Johnson & Johnson/Janssen COVID-19 vaccine to allow the FDA and CDC to review data involving six reported U.S. cases of a rare and severe type of blood clot in individuals receiving the vaccine.
More Stories Like This
Indian Health Service Joint Venture Construction Program Selects New ProjectsNew Mexico Could Be First State to Address Forced Sterilization of Native American Women
Seattle Indian Health Board Receives Global Award to Advance Women’s Health
Coming Up: A Live Stream Conversation on Reducing Drug Overdose Deaths in Indian Country
UPDATE: As Congress Moves to End Shutdown, Courts Still Sorting Out Challenges to Fully Pay SNAP in November
